Peer Reviewed Paper Calls for Stronger Safety Standards for Modified mRNA Vaccines
COVID-19 experience raises questions about manufacturing, biological persistence and long-term safety
OCALA, Fla., Oct. 26, 2026 /PRNewswire/ -- Gerry A. Quinn, Philipp Bagus, Antonio Sánchez-Bayón, Ronan Connolly, Clare Craig, Paul Frijters, Steven J. Hatfill, Anton O'Connor, Daniel Santiago, Ricardo F. Savaris, Michaéla C. Schippers, Willie Soon, Demetrios A. Spandidos, Helmut Sterz, Aristidis M. Tsatsakis, Harald Walach announce: A peer-reviewed paper published on 15 October 2026 in the Journal of Toxicology, Toxicological Vulnerabilities and Emerging Safety Signals in Modified mRNA Vaccine Technology: A Narrative Review of the COVID-19 Experience, calls for stronger safety testing, greater manufacturing transparency and sustained monitoring of modified mRNA vaccine technology. Gerry A. Quinn and colleagues examine the COVID-19 experience and argue that important toxicological questions remain unresolved—even after worldwide deployment.
Their analysis focuses on how vaccine components travel through the body, how long modified RNA and the resulting spike protein persist, and how reliably cellular machinery translates the modified genetic instructions. It also examines manufacturing changes between clinical trials and commercial production, alongside evidence of adverse events, including myocarditis.
The authors argue that safety assessment must examine the complete product: the modified RNA, its lipid nanoparticle delivery system, the proteins produced and their interactions within the body.
The implications extend beyond COVID-19. As modified mRNA technology moves into further medical applications, the paper calls for comprehensive preclinical testing, transparent reporting and long-term studies capable of identifying persistent effects and differences in individual susceptibility.
The Paper's message is summed up by Dr. Steven J. Hatfill, Former Chief Medical Officer of ASPR (HHS):
"In the over 5 years since the roll-out of the mRNA Covid-19 drugs, the mRNA platform remains inadequately tested and may continue to pose significant health risks across all patient demographics. It is critical to understand that its technological promise must be challenged by rigorous safety and efficacy studies."
Please direct all media inquiries to RMG Innovations @ https://www.rmg-innovations.com/. RMG Innovations is owned and operated by Recursion Media Group, Inc.
Media Contact:
Donald Slaughter
3527272534
SOURCE Gerry A. Quinn
Share this article